Mario Sideri
About
In The Last Decade
Mario Sideri
107 papers receiving 4.1k citations
Peers
Comparison fields: 5 of 105
- Epidemiology 2.8k
- Surgery 1.6k
- Obstetrics and Gynecology 1.3k
- Oncology 855
- Reproductive Medicine 788
Countries citing papers authored by Mario Sideri
This map shows the geographic impact of Mario Sideri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Sideri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Sideri more than expected).
Fields of papers citing papers by Mario Sideri
This network shows the impact of papers produced by Mario Sideri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Sideri. The network helps show where Mario Sideri may publish in the future.
Co-authorship network of co-authors of Mario Sideri
This figure shows the co-authorship network connecting the top 25 collaborators of Mario Sideri. A scholar is included among the top collaborators of Mario Sideri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Sideri. Mario Sideri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi). | 8 |
| 2 | 7 | |
| 3 | [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening]. | 12 |
| 4 | 7 | |
| 5 | [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. | 55 |
| 6 | 304 | |
| 7 | Health Technology assessment Report. Uso della citologia in fase liquida nello screening dei precursori del cancro del collo uterino. | 2 |
| 8 | Health Technology assessment Report: Ricerca del dna di papillomavirus umano (HPV) come test primario per lo screening dei precursori del cancro del collo dell'utero. | 2 |
| 9 | 104 | |
| 10 | Resource use and cost analysis of managing abnormal Pap smears: a retrospective study in five countries. | 4 |
| 11 | 1 | |
| 12 | 279 | |
| 13 | 235 | |
| 14 | 35 | |
| 15 | Carcinoma of the vulva. | 23 |
| 16 | Carcinoma of the ovary. | 146 |
| 17 | Medical therapy of advanced malignant epithelial tumours of the ovary | 5 |
| 18 | 23 | |
| 19 | 63 | |
| 20 | Immunophenotypic analysis of the transformation zone of human cervix. | 30 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.